Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

Efficacy of substituting innovator propafenone for its generic formulation in patients with atrial fibrillation

The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as th...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology Vol. 93; no. 12; pp. 1558 - 1560
Main Authors: Amit, Guy, Rosen, Amit, Wagshal, Avraham B., Bonneh, Dan Y., Liss, Tzvika, Grosbard, Aviva, Ilia, Reuven, Katz, Amos
Format: Journal Article
Language:English
Published: New York, NY Elsevier Inc 15-06-2004
Elsevier
Elsevier Limited
Subjects:
Aged
Aged, 80 and over
Anti-Arrhythmia Agents - therapeutic use
Atrial Fibrillation - drug therapy
Biological and medical sciences
Cardiac dysrhythmias
Cardiology. Vascular system
Cardiovascular disease
Cohort Studies
Comparative studies
Drug therapy
Drugs, Generic - therapeutic use
Emergency Service, Hospital - utilization
Female
Generic drugs
Heart
Humans
Male
Medical sciences
Patient Admission - statistics & numerical data
Propafenone - therapeutic use
Recurrence
Retrospective Studies
Therapeutic Equivalency
Treatment Outcome
Human
Arrhythmia
Atrial fibrillation
Cardiovascular disease
Generic drug
Antiarrhythmic agent
Phlebology
Excitability disorder
Efficiency
Heart disease
Formulation
Circulatory system
Cardiology
Propafenone
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical outcomes of 114 patients with atrial fibrillation who had been treated with the innovator propafenone, and in whom the drug was then replaced with generic propafenone because of cost containment, were compared. The generic formulation was found to be at least as safe and effective as the innovator drug, with regard to atrial fibrillation recurrence, emergency room and hospital admissions, and necessity for concomitant therapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2004.02.071